Introduction:
Samsung BioLogics announced plans to construct its third biopharmaceutical manufacturing plant in Songdo, Korea with a total investment of 850 billion won.
Features:
This third manufacturing plant will be a world-leading facility both in terms of capacity (180,000 liters) and production efficiency. The plant is expected to be completed by 2017 and begin operation in the fourth quarter of 2018 after validation.
Once it begins operation, Samsung BioLogics expects to become the world’s largest biologics contract manufacturing organization (CMO) with a total production capacity of 360,000 liters.
Samsung BioLogics' first plant has recently received official approval for production from the U.S. Food and Drug Administration, and its second plant is scheduled to begin operation in early 2016.
Specifications:
| Company Name | Samsung BioLogics |
| Location | Songdo, Korea |
| Type | New Manufacturing Plant |
| Estimated Cost | ₩ 850 billion |
| Operation Begins | 2018 |
